A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
A Phase II Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 (Anti-Shiga Toxin) in Pediatric Patients With Hemolytic Uremic Syndrome Associated With Shiga Toxin-producing Escherichia Coli Infection
Sponsor: Inmunova S.A.
This PHASE2 trial investigates Diarrhea-Associated Hemolytic Uremic Syndrome and Hemolytic-Uremic Syndrome and is currently completed. Inmunova S.A. leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Jul 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Oct 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Inmunova S.A.
- KLIXAR
- Linical Co., Ltd.
- PHV LATAM
For direct contact, visit the study record on ClinicalTrials.gov .